GSK: 2014 A Year Of Transition After Patent Expiration For Best-Selling Drug

02.11.2014 By Ioana David

The year 2014 will be a transition year for GlaxoSmithKline Romania, as the sales will be affected by the expiration of the patent for the best-selling drug in its portfolio, which will now see competition from generic drugs, company chief executive Pascal Prigent told ZF.

To read the full story, please login. Not a member? Subscribe here.

Reveal Romania! Business news & views.
Find out all you need by reading the entire story
To invest in Romania, you need to find out about its opportunities.
To close a strategic partnership with a Romanian company, you need to learn about its market position and whether it is a trustworthy partner
To grow here, you need to be informed

Subscribe now
Only 50 euros/month (VAT not included)
Get access to reports, news and statistics in the main sectors of Romania’s economy. Follow the strategic moves of companies operating in Romania. We will keep you updated on the latest business events.
Contact: E: newsroom@zfenglish.com (newsroom), marketing@zfenglish.com (Marketing & PR), sales@zfenglish.com (subscriptions)
T: 0040-318.256.431 (Newsroom)
0040-318.256.158, 0040-318.256.408 (Subscriptions Department)
0040-318.256.469, 0040-318.256.470 (Advertising Sales Department)
0040-318.256.427, 0040-318.256.129 (Marketing & PR)

LOGIN / Lost password?

 
Keywords:
gsk
, pascal prigent
, patent
, drug
, sales